Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
bivirkning af amoxicillin + clavulanatkalium |
Causative agent |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
allergi over for amoxicillin og clavulanatkalium |
Causative agent |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
amoxicillin + clavulanatkalium 125 mg/31 mg/5 ml sukkerfri suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
Amoxicillin 500 mg and clavulanic acid (as clavulanate potassium) 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
amoxicillin + clavulanatkalium 400 mg/57 mg/5 ml sukkerfri suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
Amoxicillin 250 mg and clavulanic acid (as clavulanate potassium) 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
co-amoxiclav 250 mg + 125 mg sukkerfri dispergibel tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
Product containing precisely amoxicillin (as amoxicillin sodium) 500 milligram and clavulanic acid (as clavulanate potassium) 100 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
Amoxicillin (as amoxicillin sodium) 1 g and clavulanic acid (as clavulanate potassium) 200 mg powder for solution for injection vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
co-amoxiclav 250 mg/62 mg/5 ml sukkerfri suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
amoxicillin med clavulanatkalium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
Amoxicillin 800 mg and clavulanate potassium 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
Amoxicillin 125 mg and clavulanic acid (as clavulanate potassium) 31.2 mg chewable tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
co-amoxiclav 200 mg/28,5 mg tyggetablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
co-amoxiclav 250 mg/62,5 mg tyggetablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
amoxicillin 400 mg + clavulanatkalium 57 mg tyggetablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
amoxicillin + clavulanatkalium 200 mg/28,5 mg/5 ml sukkerfri suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
co-amoxiclav 400 mg/57 mg/5 ml oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
amoxicillin med clavulanatkalium til oral anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
amoxicillin med clavulanatkalium til parenteral anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
Product containing precisely amoxicillin 875 milligram and clavulanic acid (as clavulanate potassium) 125 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
CWD: 600mg/5ml?? amoxicillin 600 mg + clavulanatkalium 600 mg/42,9 mg/5 ml sukkerfri suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
clavulanatkalium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
Ticarcillin + clavulanate potassium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
amoxicillin + clavulanatkalium tablet med modificeret udløsning a 1 g/62,5 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
co-amoxiclav 200 mg/28,5 mg/5 ml oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
allergi over for amoxicillin og clavulanatkalium |
Causative agent |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Amoxicillin 500 mg and clavulanic acid (as clavulanate potassium) 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
1 |
Amoxicillin 250 mg and clavulanic acid (as clavulanate potassium) 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
1 |
Amoxicillin 800 mg and clavulanate potassium 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Amoxicillin 800 mg and clavulanate potassium 125 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin 875 milligram and clavulanic acid (as clavulanate potassium) 125 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
1 |
Amoxicillin + clavulanate potassium 1g/62.5mg prolonged-release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
Amoxicillin + clavulanate potassium 250mg/125mg tablet for conventional release oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
Amoxicillin + clavulanate potassium 600mg/42.9mg/5mL conventional release oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
|
Amoxicillin 250 mg and clavulanic acid (as clavulanate potassium) 125 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Amoxicillin 500 mg and clavulanic acid (as clavulanate potassium) 125 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely amoxicillin 875 milligram and clavulanic acid (as clavulanate potassium) 125 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Amoxicillin 800 mg and clavulanate potassium 125 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin (as amoxicillin sodium) 500 milligram and clavulanic acid (as clavulanate potassium) 100 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
1 |
Amoxicillin (as amoxicillin sodium) 1 g and clavulanic acid (as clavulanate potassium) 200 mg powder for solution for injection vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin (as amoxicillin trihydrate) 50 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 12.5 milligram/1 milliliter conventional release oral suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin (as amoxicillin trihydrate) 25 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 6.25 milligram/1 milliliter conventional release oral suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely clavulanic acid (as clavulanate potassium) 200 milligram and ticarcillin (as ticarcillin disodium) 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
co-amoxiclav 400 mg/57 mg/5 ml oral suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin (as amoxicillin trihydrate) 500 milligram and clavulanic acid (as clavulanate potassium) 125 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Amoxicillin 125 mg and clavulanic acid (as clavulanate potassium) 31.2 mg chewable tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin anhydrous (as amoxicillin) 200 milligram and clavulanic acid (as clavulanate potassium) 28.5 milligram/1 each conventional release chewable tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely clavulanic acid (as clavulanate potassium) 1 milligram and ticarcillin (as ticarcillin disodium) 30 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin anhydrous (as amoxicillin) 120 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 8.58 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely amoxicillin anhydrous (as amoxicillin) 250 milligram and clavulanic acid (as clavulanate potassium) 62.5 milligram/1 each conventional release chewable tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely amoxicillin anhydrous (as amoxicillin) 400 milligram and clavulanic acid (as clavulanate potassium) 57 milligram/1 each conventional release chewable tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely amoxicillin anhydrous (as amoxicillin) 40 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 5.7 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely amoxicillin (as amoxicillin trihydrate) 250 milligram and clavulanic acid (as clavulanate potassium) 125 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin (as amoxicillin trihydrate) 875 milligram and clavulanic acid (as clavulanate potassium) 125 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin 25 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 6.25 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Amoxicillin 500 mg and clavulanic acid (as clavulanate potassium) 125 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin 80 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 11.4 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin 50 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 12.5 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin (as amoxicillin sodium) 500 milligram and clavulanic acid (as clavulanate potassium) 100 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely clavulanic acid (as clavulanate potassium) 100 milligram and ticarcillin (as ticarcillin disodium) 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Amoxicillin 400 mg and clavulanic acid (as clavulanate potassium) 57 mg chewable tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin 200 milligram and clavulanic acid (as clavulanate potassium) 28.5 milligram/1 each conventional release chewable tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Amoxicillin 250 mg and clavulanic acid (as clavulanate potassium) 62.5 mg chewable tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin 40 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 5.7 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Amoxicillin 120 mg/mL and clavulanic acid (as clavulanate potassium) 8.58 mg/mL oral suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Amoxicillin (as amoxicillin sodium) 250 mg and clavulanic acid (as clavulanate potassium) 50 mg powder for solution for injection vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely cefuroxime (as cefuroxime axetil) 500 milligram and clavulanic acid (as clavulanate potassium) 125 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin 200 milligram and clavulanic acid (as clavulanate potassium) 28.5 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin 400 milligram and clavulanic acid (as clavulanate potassium) 57 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin (as amoxicillin sodium) 500 milligram and clavulanic acid (as clavulanate potassium) 50 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin (as amoxicillin sodium) 500 milligram and clavulanic acid (as clavulanate potassium) 50 milligram/1 vial powder for conventional release solution for infusion (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amoxicillin (as amoxicillin sodium) 500 milligram and clavulanic acid (as clavulanate potassium) 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Clavulanate potassium (substance) |
Inferred relationship |
Some |
2 |